bulk pharmaceuticals importers |
||||
|
bulk pharmaceuticals importers News for 17-Oct-25 Source: MedicineNet Prevention and Wellness General Source: MedicineNet Prevention and Wellness General Source: MedicineNet Prevention and Wellness General Source: MedicineNet Prevention and Wellness General |
The Best bulk pharmaceuticals importers websiteAll the bulk pharmaceuticals importers information you need to know about is right
here. Presented and researched by http://www.md-news.net. We've searched
the information super highway far and wide to provide you with the
best bulk pharmaceuticals importers site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
bulk pharmaceuticals importers
Corporate news or equity market information on bulk pharmaceuticals importers companies will be found at websites of brokers or share traders. Articles of this kind can give you a different perspective on bulk pharmaceuticals importers which enable you to identify solid, growing bulk pharmaceuticals importers organizations compared to fly-by-night operators. It may surprise you to learn that bulk pharmaceuticals importers companies will happily add you to their press release circulation list so that you can keep right up to date with developments in the field of bulk pharmaceuticals importers including new bulk pharmaceuticals importers products which may be of particular interest to consumers like yourself. bulk pharmaceuticals importers
Once you're at the bulk pharmaceuticals importers site it's a simple matter of selecting the exact product or service you want to purchase. Nothing to it really. Whether you're just looking for information, or you're looking for something to buy right now, we've got the links to the exact bulk pharmaceuticals importers website you need. As you can tell from all the effort we've put into building our bulk pharmaceuticals importers site, it's something that we care about. You can be certain, when you follow one of the hyperlinks in the middle of this web page, or click on the pop up which might have appeared when you entered our site, we've chosen the best site about bulk pharmaceuticals importers for you to go to. Thank you for coming to our bulk pharmaceuticals importers information page. Drug Offers Hope to Cancer Patients by: ARA Content
(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community. Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer. In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow. In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs. Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer. Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy. Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce. Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.
|
|||
|
http://www.medmeet.com/ |
||||
| MD Newscast Fantasy Football Strategies Medical Presentations |